Selecting BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr. Binod Dhakal leads a discussion on patient selection for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM), focusing on how these therapies fit within an increasingly complex treatment landscape.

Dr. Prerna Mewawalla reviews emerging clinical evidence from the MajesTEC program and discusses how factors such as disease aggressiveness, patient fitness, treatment accessibility, and prior therapies influence decisions between bispecific antibodies and CAR T-cell therapy.

She highlights clinical scenarios in which bispecific antibodies may be particularly valuable, including patients with rapidly progressive disease, older or frail individuals, and those facing logistical barriers to CAR T-cell treatment.

Dr. Carol Ann Huff further explores the practical considerations involved in sequencing BCMA-targeted therapies, including the timing of T-cell collection and the potential impact of prior treatment exposure.

Together, the faculty emphasize individualized treatment planning, shared decision-making, and the importance of balancing efficacy, safety, disease characteristics, and patient preferences when selecting therapies for RRMM.